fexofenadine and Lung Neoplasms studies

fexofenadine and Lung Neoplasms

fexofenadine has been researched along with Lung Neoplasms in 1 studies

fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl
fexofenadine : A piperidine-based anti-histamine compound.

Lung Neoplasms: Tumors or cancer of the LUNG.

Research Excerpts

Excerpt	Relevance	Reference
"Osimertinib is a potent, third-generation, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR-TKI sensitizing and EGFR T790M resistance mutations."	2.90	Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. ( Calvo, E; deCastro Carpeno, J; Kim, SW; Laus, G; Lee, JS; Mann, H; Moreno, V; Vishwanathan, K; Weilert, D, 2019)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

1 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Calvo, E	1
Lee, JS	1
Kim, SW	1
Moreno, V	1
deCastro Carpeno, J	1
Weilert, D	1
Laus, G	1
Mann, H	1
Vishwanathan, K	1

Studies

Calvo, E

Lee, JS

Kim, SW

Moreno, V

deCastro Carpeno, J

Weilert, D

Laus, G

Mann, H

Vishwanathan, K

Clinical Trials (1)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO™) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed[NCT02908750]	Phase 1	24 participants (Actual)	Interventional	2017-03-02	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial

Phase

Enrollment

Study Type

Start Date

Status

An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO™) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed[NCT02908750]

Phase 1

24 participants (Actual)

Interventional

2017-03-02

Completed

[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for fexofenadine and Lung Neoplasms

Article	Year
Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. Journal of clinical pharmacology, 2019, Volume: 59, Issue:8 Topics: Acrylamides; Aged; Aniline Compounds; Anti-Allergic Agents; Antineoplastic Agents; ATP Binding Casse	2019

Article

Year

Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.

Journal of clinical pharmacology, 2019, Volume: 59, Issue:8

Topics: Acrylamides; Aged; Aniline Compounds; Anti-Allergic Agents; Antineoplastic Agents; ATP Binding Casse

2019